ADC Therapeutics (ADCT) Price & Analysis

Compare

376 Followers

ADCT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.05 - $4.06

Previous CloseN/A

Volume185.04K

Average Volume (3M)798.53K

Market Cap

$452.25M

Enterprise Value$491.04M

Total Cash (Recent Filing)$194.70M

Total Debt (Recent Filing)$334.70M

Price to Earnings (P/E)―

Beta2.42

Next Earnings

Nov 11, 2025

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.50

Shares Outstanding112,499,400

10 Day Avg. Volume1,111,478

30 Day Avg. Volume798,528

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.09

Enterprise Value/Revenue7.00

Enterprise Value/Gross Profit7.69

Enterprise Value/Ebitda-4.95

Forecast

1Y Price Target

$7.67

Price Target Upside91.75% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst recommendation is a BUY with a price target set to $10.

Clinical TrialsADCT released an update on their Phase 1b LOTIS-7 study of Zynlonta + Columvi, which included highly competitive efficacy data.

Financial PositionThe company's balance sheet resources should provide an operational runway into the second half of 2026, through multiple data catalysts.

Bears Say

Approval RisksRisks include the inability to obtain timely approval for ADCT-402 in DLBCL and slower than anticipated market uptake for ADCT-402.

Market RisksRisks include clinical setbacks, failures with other pipeline candidates, and possible medium- to long-term dilution risk.

Sales PerformanceZYNLONTA's 4Q24 sales fall relative to 3Q24.

ADC Therapeutics News

Positive Buy Rating for ADC Therapeutics Amid Promising Clinical Trials and Strong Valuation

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on ADC Therapeutics, with...

2h ago

ADCT

ADC Therapeutics Updates Strategic Focus on ZYNLONTA

ADC Therapeutics ( ($ADCT) ) just unveiled an announcement. On September 30, 2025, ADC Therapeutics released an updated...

23h ago

ADCT

ADC Therapeutics Earnings Call: Growth Amid Challenges

ADC Therapeutics Ltd (($ADCT)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

ADCT

ADC Therapeutics Reports Q2 2025 Financial Results

ADC Therapeutics Ltd ( ($ADCT) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ADCT

ADCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?

ADC Therapeutics Ltd (ADCT) is scheduled to report 2nd quarter earnings on 08/12/2025, before the market opens. Regarding...

2M ago

ADCT

ADC Therapeutics’ LOTIS-10 Study: A Potential Game-Changer in Lymphoma Treatment

Adc Therapeutics Sa (($~~ADCT)) announced an update on their ongoing clinical study. ADC Therapeutics S.A. is conducting a...

3M ago

ADCT

ADC Therapeutics files to sell 27.73M common shares for holders

17:30 EDT ADC Therapeutics (ADCT) files to sell 27.73M common shares for holders Published first on TheFly –...

3M ago

ADCT

ADC Therapeutics price target lowered to $5 from $8 at RBC Capital

RBC Capital analyst Gregory Renza lowered the firm’s price target on ADC Therapeutics (ADCT) to $5 from $8...

3M ago

ADCT

ADC Therapeutics falls -4.6%

ADC Therapeutics (ADCT) is down -4.6%, or -15c to $3.11. Published first on TheFly – the ultimate source...

3M ago

ADCT

ADC Therapeutics announces new data from Phase 2 trial of Zynlonta

ADC Therapeutics (ADCT) announced updated data from a Phase 2 multicenter investigator-initiated trial of Zynlonta to treat relapsed/refractory...

4M ago

ADCT

ADC Therapeutics price target raised to $10 from $7 at Guggenheim

Guggenheim raised the firm’s price target on ADC Therapeutics (ADCT) to $10 from $7 and keeps a Buy...

4M ago

ADCT

ADC Therapeutics Announces $100M Private Placement

ADC Therapeutics ( ($ADCT) ) has issued an announcement. On June 11, 2025, ADC Therapeutics SA announced a...

4M ago

ADCT

ADC Therapeutics to sell 13M shares at $3.53 in private placement

ADC Therapeutics (ADCT) announced that it has entered into securities purchase agreements for the sale of its equity...

4M ago

ADCT

ADC Therapeutics announces updated data from LOTIS-7 trial

ADC Therapeutics (ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and...

4M ago

ADCT

ADCT FAQ

What was ADC Therapeutics Ltd’s price range in the past 12 months?

ADC Therapeutics Ltd lowest stock price was $1.05 and its highest was $4.06 in the past 12 months.

What is ADC Therapeutics Ltd’s market cap?

ADC Therapeutics Ltd’s market cap is $452.25M.

When is ADC Therapeutics Ltd’s upcoming earnings report date?

ADC Therapeutics Ltd’s upcoming earnings report date is Nov 11, 2025 which is in 41 days.

How were ADC Therapeutics Ltd’s earnings last quarter?

ADC Therapeutics Ltd released its earnings results on Aug 12, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.492 by -$0.008.

Is ADC Therapeutics Ltd overvalued?

According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ADC Therapeutics Ltd pay dividends?

ADC Therapeutics Ltd does not currently pay dividends.

What is ADC Therapeutics Ltd’s EPS estimate?

ADC Therapeutics Ltd’s EPS estimate is -0.35.

How many shares outstanding does ADC Therapeutics Ltd have?

ADC Therapeutics Ltd has 112,499,400 shares outstanding.

What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?

ADC Therapeutics Ltd reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.492. Following the earnings report the stock price went up 9.701%.

Which hedge fund is a major shareholder of ADC Therapeutics Ltd?

Currently, no hedge funds are holding shares in ADCT

ADC Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

123.38%

Trailing 12-Months

Asset Growth

-13.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ADC Therapeutics Ltd

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADC Therapeutics (ADCT) Earnings & Revenues

Historic Earnings Reports

ADCT Company Deck

ADCT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted strong clinical trial results and a solid financial position, with significant potential for future growth. However, this is tempered by restructuring costs and increased net losses.View all ADCT earnings summaries

ADCT Stock 12 Month Forecast

Average Price Target

$7.67

▲(91.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,3.252307692307692,3.8146153846153847,4.376923076923077,4.93923076923077,5.501538461538463,6.063846153846154,6.626153846153846,7.188461538461539,7.750769230769231,8.313076923076924,8.875384615384617,9.43769230769231,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,3.073076923076923,3.456153846153846,3.8392307692307694,4.222307692307693,4.605384615384615,4.9884615384615385,5.371538461538462,5.754615384615384,6.1376923076923084,6.520769230769231,6.903846153846153,7.2869230769230775,{"y":7.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.8676923076923075,3.0453846153846156,3.223076923076923,3.4007692307692308,3.5784615384615384,3.756153846153846,3.933846153846154,4.111538461538462,4.28923076923077,4.466923076923077,4.644615384615385,4.822307692307692,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.71,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >